Anavex Life Sciences Corp. (AVXL)

Market Cap	329.01M
Revenue (ttm)	n/a
Net Income (ttm)	-43.16M
Shares Out	80.84M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,333,696
Open	4.200
Previous Close	4.120
Day's Range	4.020 - 4.205
52-Week Range	4.020 - 10.450
Beta	0.57
Analysts	Strong Buy
Price Target	40.00 (+882.8%)
Earnings Date	May 7, 2024

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL

Analyst Forecast

According to one analyst, the rating for AVXL stock is "Strong Buy" and the 12-month stock price forecast is $40.0.

Price Target

$40.0

(882.80% upside)

Analyst Consensus: Strong Buy